CTLA4 and melanoma: To further support the in-silico data, tumor sections obtained from melanoma patients that underwent anti-PD-1 and anti-CTLA-4 treatment at UM Medical Campus-Sylvester Comprehensive Cancer Center, were immuno-stained with anti-HES1 (Fig. 1Fb, d).